CA3084575A1 - Cellular compositions and methods of treatment i - Google Patents

Cellular compositions and methods of treatment i Download PDF

Info

Publication number
CA3084575A1
CA3084575A1 CA3084575A CA3084575A CA3084575A1 CA 3084575 A1 CA3084575 A1 CA 3084575A1 CA 3084575 A CA3084575 A CA 3084575A CA 3084575 A CA3084575 A CA 3084575A CA 3084575 A1 CA3084575 A1 CA 3084575A1
Authority
CA
Canada
Prior art keywords
mir
hsa
cell
cells
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3084575A
Other languages
English (en)
French (fr)
Inventor
Peter Brink
Ira Cohen
Richard Lin
Sergey DORONIN
Irina Potapova
Virginijus VALIUNAS
Dan Devine
Anthony Sandrasagra
Nick Loizos
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CA3084575A1 publication Critical patent/CA3084575A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01214—Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3084575A 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i Pending CA3084575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589764P 2017-11-22 2017-11-22
US62/589,764 2017-11-22
PCT/IB2018/001439 WO2019102268A1 (en) 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i

Publications (1)

Publication Number Publication Date
CA3084575A1 true CA3084575A1 (en) 2019-05-31

Family

ID=65003422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084575A Pending CA3084575A1 (en) 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i

Country Status (10)

Country Link
US (1) US12473547B2 (enExample)
EP (1) EP3714038A1 (enExample)
JP (2) JP7463275B2 (enExample)
KR (2) KR20200088445A (enExample)
CN (2) CN112004923A (enExample)
AU (1) AU2018372631B2 (enExample)
BR (1) BR112020010079A2 (enExample)
CA (1) CA3084575A1 (enExample)
SG (1) SG11202004680UA (enExample)
WO (1) WO2019102268A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169522A1 (en) 2006-01-13 2009-07-02 Alla Danilkovitch Mesenchymal stem cells expressing tnf-a receptor
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
JP7530836B2 (ja) * 2018-09-11 2024-08-08 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター
CN114774540B (zh) * 2020-03-30 2025-07-04 中国医学科学院肿瘤医院 包括外泌体miR-106b-3p、miR-330-5p等在肺癌诊断中的应用
CN112067805B (zh) * 2020-08-25 2023-08-22 南通大学 一种β-1,4-半乳糖基转移酶-IsiRNA在克服肝癌化疗耐药药物中的应用
CN113025714B (zh) * 2021-03-23 2022-05-24 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
WO2023019128A1 (en) * 2021-08-09 2023-02-16 The Trustees Of The University Of Pennyslvania Optimizing t cell differentiation state with micrornas
CN114085817B (zh) * 2021-11-26 2025-04-15 三代康年(上海)医疗科技有限公司 一种包载microRNA的外泌体的制备方法及其产品和应用
US20250333758A1 (en) * 2021-12-15 2025-10-30 Genans Biotechnology Co., Ltd Microglia having car and use thereof
WO2024196812A1 (en) * 2023-03-20 2024-09-26 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived micro-ribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders
CN118831092A (zh) * 2024-09-19 2024-10-25 天津市第五中心医院 miR-200b-3p在制备治疗子宫内膜癌的药物中的应用
CN119144728B (zh) * 2024-11-19 2025-04-29 四川大学华西医院 原发性肝癌的MicroRNA标志物的引物、试剂盒和应用

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
DK0952792T3 (da) 1994-06-06 2003-12-08 Osiris Therapeutics Inc Biomatrix til vævsregeneration
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643736A (en) 1995-02-06 1997-07-01 Osiris Therapeutics, Inc. Monoclonal antibodies for human osteogenic cell surface antigens
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
EP1304113B1 (en) 1995-03-28 2007-07-25 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
PT868505E (pt) 1995-11-16 2005-06-30 Univ Case Western Reserve Inducao condrogenica in vitro de celulas estaminais mesenquimais humanas
US6482231B1 (en) 1995-11-20 2002-11-19 Giovanni Abatangelo Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
ATE439849T1 (de) 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
JP2000508922A (ja) 1996-04-26 2000-07-18 ケース ウエスターン リザーブ ユニバーシティ 間葉幹細胞を用いる皮膚再生
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
AU5436998A (en) 1996-11-15 1998-06-03 Osiris Therapeutics, Inc. MSC-megakaryocyte precursor composition and method of isolating MSCs asso ciated with isolated megakaryocytes by isolating megakaryocytes
PT1028737E (pt) 1997-07-03 2007-07-11 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas de sangue periférico
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
EP1007631B2 (en) 1997-07-14 2009-02-18 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
CA2302339A1 (en) 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
US6355239B1 (en) 1998-03-13 2002-03-12 Osiris Therapeutics, Inc. Uses for non-autologous mesenchymal stem cells
DE69929681T2 (de) 1998-03-18 2006-10-26 Osiris Therapeutics, Inc. Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
AU2904199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
AU4094099A (en) 1998-05-22 1999-12-13 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
AU4221399A (en) 1998-05-29 1999-12-13 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
WO1999064566A2 (en) 1998-06-08 1999-12-16 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
BR9912662A (pt) 1998-07-31 2001-06-05 Genzyme Corp Melhoria de função cardìaca por transplante de célula de ramo mesenquimal
JP2002529508A (ja) 1998-11-13 2002-09-10 オシリス セラピューティクス，インコーポレイテッド 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物
US6761887B1 (en) 1998-11-16 2004-07-13 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
WO2000049136A1 (en) 1999-02-17 2000-08-24 United States Surgical Genetically altered mesenchymal stem cells and methods of use thereof
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP1218489B1 (en) 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CA2400485C (en) 2000-02-26 2014-04-29 Artecel Sciences, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US20020005205A1 (en) 2000-04-25 2002-01-17 Barry Francis P. Joint repair using mesenchymal stem cells
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
CA2429502A1 (en) 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7144729B2 (en) 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1279738A1 (en) 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
JP4412537B2 (ja) 2001-08-22 2010-02-10 秦 順一 骨の再生方法
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
US20050048036A1 (en) 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
DK1921133T3 (en) 2001-12-07 2015-08-24 Cytori Therapeutics Inc System for processing lipoaspiratceller
US20050008626A1 (en) 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2003059272A2 (en) 2002-01-14 2003-07-24 Henry Ford Health System Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
CA2478616C (en) 2002-03-26 2012-05-29 Oncolytics Biotech Inc. Use of adenoviruses mutated in the va genes for cancer treatment
JP2005521398A (ja) 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
CN1187058C (zh) 2002-04-16 2005-02-02 中国医学科学院血液学研究所泰达生命科学技术研究中心 用于修复中枢神经损伤的干细胞制剂及其制造方法
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
CA2489212C (en) 2002-06-14 2012-08-14 Cartela Ab Marker for stem cells and its use
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004007697A2 (en) 2002-07-16 2004-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of implanting mesenchymal stem cells for tissue repair and formation
EP1545219A4 (en) 2002-07-23 2009-09-30 Boston Scient Ltd REGENERATION CELL THERAPY
WO2004016779A1 (en) 2002-08-17 2004-02-26 Hae-Young Suh A method for transdifferentiating mesenchymal stem cells into neuronal cells
AU2003270427A1 (en) 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
CN1536075A (zh) 2003-04-09 2004-10-13 中国人民解放军军事医学科学院野战输 一种诱导骨髓间充质干细胞向胰岛样细胞分化的方法
CH700956B1 (de) 2003-05-08 2010-11-15 Cellartis Ab Gefrierkonservierung menschlicher, von Blastocysten abgeleiteten Stammzellen nach dem Verfahren der Vitrifizierung im geschlossenen Röhrchen.
JP2007514445A (ja) * 2003-12-17 2007-06-07 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 宿主細胞から標的細胞へのギャップジャンクションを介したＤＮＡまたはＲＮＡの送達、及びアンチセンスまたはｓｉＲＮＡのための細胞ベースの送達システム
AU2005227295A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
ES2385450T3 (es) 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Células madre mesenquimatosas y sus utilizaciones
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US20060063141A1 (en) 2004-09-17 2006-03-23 Mcgann Locksley E Method of cryopreserving cells
EP3327116A1 (en) 2005-04-12 2018-05-30 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2006112365A1 (ja) 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療
US20100034793A1 (en) 2005-04-19 2010-02-11 The John Hopkins University Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood
PL1888123T3 (pl) 2005-06-08 2013-06-28 Janssen Biotech Inc Terapia komórkowa chorób degeneracyjnych oka
WO2007027156A1 (en) 2005-09-02 2007-03-08 Agency For Science, Technology And Research Method of deriving mesenchymal stem cells
US7888119B2 (en) 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20090169522A1 (en) 2006-01-13 2009-07-02 Alla Danilkovitch Mesenchymal stem cells expressing tnf-a receptor
CA2705450A1 (en) 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al Stem cells for treating lung diseases
AU2007243221A1 (en) 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
US20100047216A1 (en) * 2006-07-21 2010-02-25 Glenn Gaudette Compositions of late passage mesenchymal stem cells (mscs)
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
HUE036745T2 (hu) 2006-11-03 2018-07-30 Multiple Sclerosis Res Center Of New York Csontvelõ eredetû mesenchimális õssejtek, mint a neurális progenitor sejtek forrásai
ATE496627T1 (de) 2006-11-03 2011-02-15 Aastrom Biosciences Inc Mischzell-populationen für die gewebereparatur und trenntechnik für die zellaufbereitung
CA2671194A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
EP2132299A4 (en) 2007-03-01 2010-03-10 Cryo Cell Int OBTAINING, ISOLATING, AND CRYOKON SUSPENSION OF ENDOMETRY / MENSTRUATION CELLS
DK2137301T3 (da) 2007-03-14 2011-09-12 Inst Catala D Oncologia Adenovirus med mutationer i det endoplasmatiske reticulums retentionsdomæne for E3-19K-proteinet samt deres anvendelse ved cancerbehandling
WO2008141177A1 (en) 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Methods and compositions for the treatment of sarcoma
US9095562B2 (en) 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
AU2009279736A1 (en) 2008-08-04 2010-02-11 Allocure, Inc. Mesenchymal stromal cell populations and methods of isolating and using same
AU2009281809B2 (en) 2008-08-14 2015-09-17 Mesoblast International Sarl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
US20120114618A1 (en) * 2009-03-26 2012-05-10 The Regents Of The University Of California Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA2776882A1 (en) 2009-10-06 2011-04-14 The Cohen Mcniece Foundation Preparation and use of stromal cells for treatment of cardiac diseases
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
WO2012012570A2 (en) 2010-07-20 2012-01-26 University Of Southern California High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon
JP2013536860A (ja) 2010-08-31 2013-09-26 クック・ジェネラル・バイオテクノロジー・エルエルシー 動物の疾病の治療のための全身的、同種間幹細胞治療
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
AU2011325439B2 (en) 2010-11-02 2015-07-23 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Methods and vectors for cell immortalisation
US8748470B2 (en) * 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
FI125055B (fi) 2011-04-07 2015-05-15 Oy Langh Ship Ab Kontti
ES2716015T3 (es) 2011-06-03 2019-06-07 Mesoblast Inc Procedimiento para tratar los efectos de un accidente cerebrovascular
HUE039236T2 (hu) 2011-07-06 2018-12-28 Cell Therapy Ltd Mezodermális eredetû progenitorsejtek
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201606356YA (en) 2012-02-02 2016-09-29 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens
US20150024966A1 (en) * 2012-02-22 2015-01-22 Brainstem Biotec Ltd. Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
PL2970912T3 (pl) 2013-03-13 2019-08-30 Wisconsin Alumni Research Foundation Sposoby i materiały do hematopoetyczno-śródbłonkowego różnicowania ludzkich pluripotentnych komórek macierzystych w zdefiniowanych warunkach
ES2878549T3 (es) 2013-06-18 2021-11-19 Dnatrix Inc Adenovirus oncolítico para su uso en el tratamiento del cáncer cerebral
US20160199413A1 (en) 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
SG11201603407VA (en) 2013-11-04 2016-05-30 Isopogen Pty Ltd Cell culture method
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
JP6882161B2 (ja) 2014-04-07 2021-06-02 メゾブラスト・インターナショナル・エスアーエールエル 改善された幹細胞組成物
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
US9574211B2 (en) * 2014-05-13 2017-02-21 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2016086020A1 (en) * 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
KR102660505B1 (ko) 2014-12-23 2024-04-25 메조블라스트 인터내셔널 에스에이알엘 진행성 심부전증의 예방
CN113957043A (zh) 2015-03-04 2022-01-21 迈索布拉斯特国际有限公司 间充质干细胞的细胞培养方法
CA2984987C (en) 2015-05-05 2023-10-10 Mesoblast International Sarl Potency assay
WO2017132358A1 (en) 2016-01-26 2017-08-03 Kansas State University Research Foundation Methods for isolation and expansion of umbilical cord mesenchymal stem cells
EP3419635B1 (en) 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
WO2017165641A1 (en) * 2016-03-23 2017-09-28 The Trustees Of Columbia University In The City Of New York CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US20180021380A1 (en) 2016-07-21 2018-01-25 Sungkwang Medical Foundation Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same
EP4403229A3 (en) 2016-07-29 2024-08-14 Ohio State Innovation Foundation Expression of pten-long with oncolytic viruses
JP7358236B2 (ja) 2016-09-19 2023-10-10 ユニヴァーシティ オブ サウス フロリダ 腫瘍溶解性ウイルスを腫瘍に標的化する方法
US20200108099A1 (en) 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
WO2018182612A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease
BR112019022901A2 (pt) 2017-05-04 2020-05-19 Mesoblast International Sàrl precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
CL2017002357A1 (es) 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
WO2019093481A1 (ja) 2017-11-09 2019-05-16 北海道公立大学法人札幌医科大学 組織再生用医薬及びその製造方法
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
CN108715833B (zh) 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
KR20200015174A (ko) 2018-08-03 2020-02-12 이동희 3차원 세포 배양 지지체 및 이를 포함하는 줄기세포 배양 조성물
CA3125308A1 (en) 2019-01-02 2020-07-09 Mesoblast International Sarl Method for treating lower back pain
US20220079991A1 (en) 2019-01-03 2022-03-17 Mesoblast International Sárl Method for improving visual acuity
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
SG11202112449SA (en) 2019-05-23 2021-12-30 Mesoblast Int Sarl Functional recovery from cerebral infarction
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
US20230097931A1 (en) 2020-02-19 2023-03-30 Mesoblast International Sárl Method for treating chronic graft versus host disease
CN111297899A (zh) 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
KR20220152240A (ko) 2020-03-11 2022-11-15 메조블라스트 인터내셔널 에스에이알엘 염증성 장 질환 ii의 치료 방법
US20230172991A1 (en) 2020-03-11 2023-06-08 Mesoblast International Sárl Method for treating inflammatory bowel disease i
BR112022020042A2 (pt) 2020-04-03 2022-11-22 Mesoblast Int Sarl Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
CN115997005A (zh) 2020-06-11 2023-04-21 迈索布拉斯特国际有限公司 间充质谱系前体或干细胞的3d培养
KR20230046298A (ko) 2020-08-10 2023-04-05 메조블라스트 인터내셔널 에스에이알엘 세포 조성물 및 치료 방법
EP4192482A1 (en) 2020-08-10 2023-06-14 Mesoblast International Sàrl A composition comprising mesenchymal precursor or stem cells and their use
KR20230119676A (ko) 2020-12-15 2023-08-16 메조블라스트 인터내셔널 에스에이알엘 클래스 ii 심부전 환자의 진행성 심부전 치료 방법
CN112522191B (zh) 2020-12-18 2023-05-12 云南中科灵长类生物医学重点实验室 一种间充质干细胞的培养方法
CA3205638A1 (en) 2021-01-22 2022-07-28 Silviu Itescu Opioid sparing compositions and methods of using the same
KR20240001173A (ko) 2021-04-23 2024-01-03 메조블라스트 인터내셔널 에스에이알엘 중간엽 계통 전구체 또는 줄기 세포를 이용하는 특정 환자의 급성 호흡 곤란 증후군(ards)의 치료 방법
CN120603931A (zh) 2022-12-09 2025-09-05 迈索布拉斯特国际有限公司 预先许可的组合物和细胞培养方法

Also Published As

Publication number Publication date
US12473547B2 (en) 2025-11-18
JP7463275B2 (ja) 2024-04-08
JP2024091644A (ja) 2024-07-05
JP2021507683A (ja) 2021-02-25
AU2018372631A1 (en) 2020-05-21
KR20250051794A (ko) 2025-04-17
AU2018372631B2 (en) 2025-06-05
US20210163932A1 (en) 2021-06-03
KR20200088445A (ko) 2020-07-22
BR112020010079A2 (pt) 2020-11-03
EP3714038A1 (en) 2020-09-30
CN112004923A (zh) 2020-11-27
SG11202004680UA (en) 2020-06-29
WO2019102268A1 (en) 2019-05-31
CN119033819A (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
US12473547B2 (en) Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer
US10752883B2 (en) Generation of neural stem cells and motor neurons
US9862949B2 (en) Method for the inhibition of angiogenesis
EP3401393B1 (en) Micrornas for the generation of astrocytes
JP5681955B2 (ja) 短いｒｎａ分子
US20150216892A1 (en) Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US12281310B2 (en) Use of trinucleotide repeat RNAs to treat cancer
CN103476947A (zh) 寡聚体的增强的生物分布
WO2010151755A2 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
CN108367020B (zh) 通过miR-200家族抑制来抑制肿瘤的方法
US8796238B2 (en) Short RNA mimetics
EP4282963A1 (en) Nucleic acid modified biological cell with expansion-dependent gene expression
KR20250016667A (ko) Psme4 억제제를 포함하는 중간엽 줄기세포의 조골세포 분화 촉진용 조성물
US20220251566A1 (en) Cells engineered for oligonucleotide delivery, and methods for making and using thereof
WO2024151776A2 (en) Compositions and methods for treating a neurologic disease using dopaminergic neurons with enhanced anti-inflammatory activity
EP4649150A1 (en) Cell context-specific gene regulation using inhibitory rnas
US9273313B2 (en) Activation of quiescent stem cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231117